Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2018

Open Access 01-02-2018 | Original Article

Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses

Authors: Rebecca Clark-Snow, Mary Lou Affronti, Cynthia N. Rittenberg

Published in: Supportive Care in Cancer | Issue 2/2018

Login to get access

Abstract

Purpose

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients with use of guideline-recommended antiemetic regimens. However, studies have suggested that adherence to antiemetic guidelines is suboptimal. Oncology nurses, as part of a multidisciplinary team, can help promote appropriate antiemetic prophylaxis. Therefore, nurses were surveyed to assess antiemetic guideline awareness and practice patterns of antiemetic use, determine adherence to guideline recommendations, and query barriers to adherence.

Methods

In September 2015, 531 US-based oncology nurses participated in an online survey administered and analyzed by ONS:Edge.

Results

Nurses were most familiar with National Comprehensive Cancer Network (73%) and American Society of Clinical Oncology (48%) antiemetic guidelines. While most (77%) felt that antiemetics prescribed were consistent with guideline recommendations, practice patterns of antiemetic use revealed low adherence to those guidelines, particularly during the delayed (25–120 h) phase following highly emetogenic chemotherapy, where only 25% of nurses reported administration of guideline-recommended agents. Overutilization of phenothiazines and benzodiazepines was common. Only 17% of respondents reported that most (> 75%) of their patients have CINV optimally controlled; 39% reported between 6 and 20% of patients have an alteration in their chemotherapy due to CINV, and reports of emergency department/hospital visits due to poorly controlled CINV were high. The predominant barrier interfering guideline-recommended antiemetic prophylaxis was reported as physician preference (71%).

Conclusions

This survey revealed an opportunity to increase awareness of antiemetic guidelines and a critical need to address barriers interfering with utilization of guideline-recommended antiemetic agents in order to optimize CINV control for patients undergoing emetogenic chemotherapy.
Appendix
Available only for authorised users
Literature
1.
Navari R, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. NEJM 374:1356–1367CrossRefPubMed
2.
ASCO 50th anniversary poll names top 5 advances past 50 years. The ASCO Post, October 15, 2014
3.
Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26(6):1081–1090CrossRefPubMed
4.
Roila F, Molassiotis A, Herrstedt J, et al. (2016) MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:119–133
5.
Hesketh PJ, Bohlke K, Lyman G et al (2016) Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol 34(4):381–386CrossRefPubMed
6.
7.
Aapro M, Molassiotis A, Dicato M et al (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23(8):1986–1992CrossRefPubMed
8.
Gilmore JW, Peacock NW, Gu A et al (2014) Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community oncology practice: INSPIRE study. J Oncol Pract 10(1):68–74CrossRefPubMed
9.
Affronti ML, Schneider SM, Schlundt S et al (2014) Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. Support Care Cancer 22(7):1897–1905CrossRefPubMedPubMedCentral
10.
Roeland E, Aapro M, Schwartzberg L (2015) Advances in the management of chemotherapy-Induced nausea and vomiting: new data from recent and ongoing trials. Clinical Roundtable Monograph. Clinical Advances in Hematology & Oncology
11.
de Boer-Dennert M, de Wit R, Schmitz PIM et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055–1061CrossRefPubMedPubMedCentral
12.
Schwartzberg L, Harrow B, Lal L et al (2015) Resource utilization for chemotherapy-induced nausea and vomiting events for patients with solid tumors treated with antiemetic regimens. Am Health Drug Benefits 8(5):273–282PubMedPubMedCentral
13.
14.
Van Laar ES, Desai JM, Jatoi A (2015) Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support Care Cancer 23:151–157CrossRefPubMedPubMedCentral
15.
Dranitsaris G et al (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: development of a practical prediction tool I Acute nausea and vomiting. J Support Oncol 7:W1–W8
16.
Petrella T et al (2009) Identifying patients at high risk for nausea and vomiting after chemotherapy: development of a practical prediction tool II Delayed nausea and vomiting. J Support Oncol 7:W9–W16
17.
Dranitsaris G, Bouganim N, Milano C et al (2013) Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting. J Support Oncol 11(1):14–21PubMed
18.
Molassiotis A, Stamataki Z, Kontopantelis E et al (2013) Development and preliminary validation of risk prediction model for chemotherapy-induced nausea and vomiting. Support Care Cancer 21(10):2759–2767CrossRefPubMed
Metadata
Title
Chemotherapy-induced nausea and vomiting (CINV) and adherence to antiemetic guidelines: results of a survey of oncology nurses
Authors
Rebecca Clark-Snow
Mary Lou Affronti
Cynthia N. Rittenberg
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3866-6

Other articles of this Issue 2/2018

Supportive Care in Cancer 2/2018 Go to the issue

Original Article

Management of superior vena cava syndrome in critically ill cancer patients

Commentary

Longitudinal assessment of the impact of adapted physical activity on upper limb disability and quality of life in breast cancer survivors from an Italian cohort

Original Article

What type and dose of antidepressants are cancer and non-cancer inpatients being prescribed: a retrospective case-control study at an Australian tertiary hospital

Original Article

Development and feasibility of a web application to monitor patients’ cancer-related pain

Original Article

Guidance for establishing an integrative oncology service in the Australian healthcare setting—a discussion paper

Original Article

Madarosis: a qualitative study to assess perceptions and experience of Australian patients with early breast cancer treated with taxane-based chemotherapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits